Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Glycogen synthase kinase 3 beta constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling, and regulation of transcription factors and microtubules. The Glycogen Synthase Kinase 3 Beta pipeline drugs market research report outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

GSK3B Pipeline Drugs Market Segmentation by Therapy Areas

The key therapy areas in the GSK3B pipeline drugs market are the central nervous system, oncology, genetic disorders, musculoskeletal disorders, ear nose throat disorders, ophthalmology, and undisclosed.

GSK3B Pipeline Drugs Market Analysis, by Therapy Areas, 2022 (%)

GSK3B Pipeline Drugs Market Analysis, by Therapy Areas

For more GSK3B pipeline drugs therapy area insights, download a free report sample

GSK3B Pipeline Drugs Market Segmentation by Mechanism of Actions

The key mechanism of action in the GSK3B pipeline drugs market is Glycogen Synthase Kinase 3 Beta Inhibitor.

GSK3B Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the GSK3B pipeline drugs market are oral, intravenous, intratympanic, parenteral, and sublingual.

GSK3B Pipeline Drugs Market Analysis, by Routes of Administration, 2022 (%)

GSK3B Pipeline Drugs Market Analysis, by Routes of Administration

For more GSK3B pipeline drugs routes of administration insights, download a free report sample

GSK3B Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the GSK3B pipeline drugs market are small molecule and synthetic peptide.

GSK3B Pipeline Drugs Market Analysis, by Molecule Types, 2022 (%)

GSK3B Pipeline Drugs Market Analysis, by Molecule Types

For more GSK3B pipeline drugs molecule type insights, download a free report sample

Competitive Landscape

Some of the leading companies in the GSK3B pipeline drugs market are Actuate Therapeutics Inc, Alzamend Neuro Inc, AMO Pharma Ltd, Angelini Spa, Ankar Pharma SL, Avenzoar Pharmaceuticals Inc, CerebraMed, Collaborative Medicinal Development LLC, Frequency Therapeutics Inc, and IGC Pharma LLC.

GSK3B Pipeline Drugs Market Analysis, by Companies, 2022 (%)

GSK3B Pipeline Drugs Market Analysis, by Companies

To know more about the GSK3B pipeline drugs companies, download a free report sample

Glycogen Synthase Kinase 3 Beta Pipeline Drugs Market Report Overview

Key Therapy Areas Central Nervous System, Oncology, Genetic Disorders, Musculoskeletal Disorders, Ear Nose Throat Disorders, Ophthalmology, and Undisclosed
Key Mechanism of Actions Glycogen Synthase Kinase 3 Beta Inhibitor
Key Routes of Administration Oral, Intravenous, Intratympanic, Parenteral, and Sublingual
Key Molecule Types Small Molecule and Synthetic Peptide
Leading Companies Actuate Therapeutics Inc, Alzamend Neuro Inc, AMO Pharma Ltd, Angelini Spa, Ankar Pharma SL, Avenzoar Pharmaceuticals Inc, CerebraMed, Collaborative Medicinal Development LLC, Frequency Therapeutics Inc, and IGC Pharma LLC

Segments Covered in the Report

GSK3B Pipeline Drugs Market Therapy Areas Outlook

  • Central Nervous System
  • Oncology
  • Genetic Disorders
  • Musculoskeletal Disorders
  • Ear Nose Throat Disorders
  • Ophthalmology
  • Undisclosed

GSK3B Pipeline Drugs Market Mechanism of Actions Outlook

  • Glycogen Synthase Kinase 3 Beta Inhibitor

GSK3B Pipeline Drugs Market Routes of Administration Outlook

  • Oral
  • Intravenous
  • Intratympanic
  • Parenteral
  • Sublingual

GSK3B Pipeline Drugs Market Molecule Types Outlook

  • Small Molecule
  • Synthetic Peptide

Scope

This report provides:

  • A snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1).
  • Reviews of Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects.
  • Assessment of Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Summaries of all the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics.

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1). Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Actuate Therapeutics Inc
Alzamend Neuro Inc
AMO Pharma Ltd
Angelini Spa
Ankar Pharma SL
Avenzoar Pharmaceuticals Inc
CerebraMed
Collaborative Medicinal Development LLC
Frequency Therapeutics Inc
IGC Pharma LLC
InnoBioscience LLC
Mercaptor Discoveries Inc
Novosteo Inc
Park of Active Molecules
Recursion Pharmaceuticals Inc
Zovis Pharmaceuticals

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC

2.7.11.26 or EC

2.7.11.1) – Overview

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC

2.7.11.26 or EC

2.7.11.1) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC

2.7.11.26 or EC

2.7.11.1) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC

2.7.11.26 or EC

2.7.11.1) – Companies Involved in Therapeutics Development

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC

2.7.11.26 or EC

2.7.11.1) – Drug Profiles

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC

2.7.11.26 or EC

2.7.11.1) – Dormant Products

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC

2.7.11.26 or EC

2.7.11.1) – Discontinued Products

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC

2.7.11.26 or EC

2.7.11.1) – Product Development Milestones

Featured News & Press Releases

Sep 21, 2022: IGC announces issuance of second patent for the treatment of Alzheimer’s Using THC

Sep 16, 2022: Quince Therapeutics presents preclinical data at MHSRS 2022 demonstrating preclinical efficacy of bone-targeting platform for traumatic bone injury

Sep 12, 2022: Quince Therapeutics presents preclinical data at ASBMR 2022 demonstrating application of bone-targeting platform for spinal fusion and bone cancer indications

Aug 30, 2022: Quince Therapeutics presents preclinical data at OI 2022 demonstrating potential of a targeted anabolic for accelerated bone healing of osteogenesis imperfecta fractures

Jul 18, 2022: Alzamend Neuro receives positive pre-IND response from FDA for AL001 treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder

Jun 03, 2022: Innovative hearing restoration trial launches at the Medical College of Wisconsin

May 17, 2022: Alzamend Neuro announces pre-IND submission for AL001 as a treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder

May 05, 2022: Alzamend Neuro announces initiation of phase IIA multiple ascending dose clinical trial for AL001 treatment of dementia related to Alzheimer’s

Apr 11, 2022: Alzamend Neuro contracts with Altasciences and iResearch Atlanta to manage and conduct its phase IIA study in patients with Alzheimer’s

Mar 28, 2022: Actuate Therapeutics announces poster presentations at the 2022 AACR Annual Meeting

Mar 28, 2022: Alzamend Neuro announces full data set from phase 1 first-in-human clinical trial for AL001 treatment of Dementia Related to Alzheimer’s

Mar 11, 2022: ENTA conducting clinical trial of investigational regenerative medication to restore hearing function in sensorineural hearing loss (SNHL) patients

Mar 01, 2022: Actuate Therapeutics announces first patient enrolled in Phase 2 clinical trial of elraglusib plus retifanlimab as investigational first line therapy for patients with advanced pancreatic cancer

Feb 07, 2022: Actuate Therapeutics announces initiation of a multicenter randomized trial of elraglusib plus FOLFIRINOX as first line therapy for advanced pancreatic cancer

Dec 22, 2021: AMO Pharma announces expansion of pivotal REACH-CDM study in congenital myotonic dystrophy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.